2-amino-4-phosphonobutyric acid has been researched along with Atherosclerotic Parkinsonism in 1 studies
2-amino-4-phosphonobutyric acid: glutamate antagonist in locust muscle; structure; do not confuse with L-AP4, which is the propionic acid version
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cuomo, D | 1 |
| Martella, G | 1 |
| Barabino, E | 1 |
| Platania, P | 1 |
| Vita, D | 1 |
| Madeo, G | 1 |
| Selvam, C | 1 |
| Goudet, C | 1 |
| Oueslati, N | 1 |
| Pin, JP | 1 |
| Acher, F | 1 |
| Pisani, A | 1 |
| Beurrier, C | 1 |
| Melon, C | 1 |
| Kerkerian-Le Goff, L | 1 |
| Gubellini, P | 1 |
1 other study available for 2-amino-4-phosphonobutyric acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Electrophysiology; | 2009 |